Could a drug tame excess cortisol in a common hormone disorder?
NCT ID NCT07138274
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether the drug metyrapone can safely lower cortisol levels in people with mild autonomous cortisol secretion (MACS), a condition where the adrenal glands produce too much cortisol. Participants will receive either metyrapone or a placebo for a short period, and researchers will measure changes in hormone ratios and daily cortisol patterns. The goal is to see if metyrapone can help control the hormone imbalance and improve health outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- metyrapone
- What this could lead to
- If successful, metyrapone could offer a way to manage cortisol levels in people with MACS, potentially reducing related health risks.
- What could go wrong
- This is an early Phase 2 study with only 90 participants, so results may not apply broadly. Metyrapone can cause side effects like nausea or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTONOMOUS CORTISOL SECRETION (ACS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes drug fix lingering health issues after adrenal surgery?
- New pill targets hormone imbalance from adrenal tumors
- New pill aims to tame hidden cortisol problem
- Can a diabetes drug replace surgery for a rare hormone disorder?
- Researchers hunt for best test to spot hidden hormone problem in adrenal tumors
- Drug showdown: which pill tames cortisol better?